# Citations for Research Query

**Query:** # Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** EGFR-Mutant Non-Small Cell Lung Cancer
- **MONDO ID:**  (if available)
- **Category:** 

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **EGFR-Mutant Non-Small Cell Lung Cancer**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs

**Provider:** falcon
**Generated:** 2026-01-24T18:51:50.113603

1. halder2023targetingtheegfr pages 4-6
2. zhang2024overcomingegfrtkiresistance pages 1-2
3. yuan2025newadvancesin pages 22-22
4. tian2025egfrmutationsin pages 6-7
5. lim2025targetingthetumor pages 20-22
6. romaniello2025strategiestoovercome pages 1-2
7. lim2025targetingthetumor pages 2-3
8. li2025multimodalomicsanalysis pages 1-2
9. EMT
10. https://doi.org/10.1080/14728222.2023.2218613
11. https://doi.org/10.1016/j.pccm.2024.08.002
12. https://doi.org/10.62347/wtmu5537
13. https://doi.org/10.3892/ol.2025.15121
14. https://doi.org/10.3390/biomedicines13020470
15. https://doi.org/10.3390/ijms26072957
16. https://doi.org/10.1016/j.jncc.2024.06.004
17. https://doi.org/10.1038/s41417-024-00761-z
18. https://doi.org/10.1186/s12943-023-01780-4
19. https://doi.org/10.1038/s41419-024-06945-7
20. https://doi.org/10.1038/s41418-024-01317-2
21. https://doi.org/10.21037/tlcr-23-98;
22. https://doi.org/10.3390/ijms25115917
23. https://doi.org/10.32604/or.2025.059311
24. https://doi.org/10.1038/s41418-024-01317-2.
25. https://doi.org/10.21037/tlcr-23-98
26. https://doi.org/10.32604/or.2025.059311.
27. https://doi.org/10.1080/14728222.2023.2218613,
28. https://doi.org/10.1016/j.pccm.2024.08.002,
29. https://doi.org/10.3390/biomedicines13020470,
30. https://doi.org/10.3390/ijms26072957,
31. https://doi.org/10.32604/or.2025.059311,
32. https://doi.org/10.62347/wtmu5537,
33. https://doi.org/10.3892/ol.2025.15121,